01:50 PM EDT, 06/15/2026 (MT Newswires) -- Healthcare stocks declined Monday afternoon with the NYSE Healthcare Index dropping 0.7% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.5%.

The iShares Biotechnology ETF (IBB) rose 0.5%.

In sector news, the Centers for Medicare & Medicaid Services proposed a rule to establish a permanent regulatory framework for the Medicare Drug Price Negotiation Program beginning with the 2029 price-applicability year, shifting to codified regulations from implementation through annual guidance.

In corporate news, Neumora Therapeutics ( NMRA ) shares tumbled 52% after the company halted development of its major depressive disorder treatment navacaprant after two Phase 3 trials failed to meet their primary and key secondary endpoints. Neumora also announced it will reduce its workforce by 35%.

Elicio Therapeutics ( ELTX ) shares plunged 72% after the company said a Phase 2 study assessing the experimental pancreatic cancer therapy ELI-002 7p did not meet the prespecified primary endpoint of disease-free survival.

Cuprina Holdings ( CUPR ) shares more than doubled after a subsidiary obtained 510(k) clearance from the US Food and Drug Administration for its Medifly Maggots product that uses Lucilia cuprina larvae in maggot debridement therapy.